Dr Jean-Christophe Delumeau graduated in medicine, toxicology, pharmacology, applied statistics and methodology of clinical trials, from universities of Rennes and Paris (France). After completing residency, he joined a research program on intracellular signaling at the French National Institute of Medical Research. He obtained PhD from University Pierre and Marie Curie (Paris VI).

From 1991, he moved to clinical research, working in Basel (Roche, Novartis), Paris and Tokyo (Rhone-Poulenc) where he conducted the multinational trials in neurodegenerative diseases and cerebrovascular disorders.

From 2002, he took the responsibility of the pharmacovigilance department of Bayer Yakuhin (Japan) until his appointment in 2009 as head of Pharmacovigilance for Asia-Pacific and China, based in Beijing then Singapore. In July 2017, he was appointed head of Pharmacovigilance Policy Strategy, extending his safety regulatory scope beyond Asia, especially to Latin America, Eastern Europe, Middle East and Africa, also joining as co-chairperson the International Pharmacovigilance Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Since October 2016, Dr Jean-Christophe Delumeau is serving as Board and Executive Committee Member of the International Society of Pharmacovigilance, also coordinating ISoP’s Special Interest Group on Risk Minimisation methods for Asian Countries.